Amplifon SpA shares plunged to their weakest point since late 2016 after the Italian hearing-aid retailer disclosed a €2.3 billion acquisition of GN Hearing, a move that triggered immediate reassessments from bank analysts.
The stock was trading at €8.02 on Wednesday, a decline from €10.52 on March 13, the last session before the deal was revealed. For context on the stock's prior performance, Amplifon reached a peak of €47.45 in December 2021.
Under the terms announced on March 16, Amplifon will pay GN Store Nord €1.69 billion in cash for GN Hearing. The transaction will be financed by up to €1 billion in debt and an equity raise of as much as €0.75 billion, together with the issuance of 56 million new Amplifon shares. Those shares would give GN an approximate 16% stake in the enlarged group.
The structure of the deal does not require shareholder approval by either party as a baseline condition, though Amplifon has indicated it may seek shareholder consent if the equity raise exceeds 20% of its share capital. Closing is expected by the end of 2026, subject to regulatory approvals and completion of the GN Hearing carve-out.
In response to the acquisition, Barclays reduced its rating on Amplifon to "equal weight" from "overweight" and lowered its price target to €10, describing the deal as "a big strategic change" for a company the bank had previously supported for its retail-only model. Barclays said it had valued Amplifon's retail-focused approach for the pricing power and access to the latest product innovations across manufacturers without taking on R&D risk.
Jefferies also downgraded Amplifon, moving to "hold" from "buy" and setting a price target of €8. The bank highlighted the potential supply of new shares into the market, noting that close to 40% of the current share count could be issued by year-end. Jefferies warned that, given GN's stated position that it does not view itself as a long-term holder, GN is likely to sell its stake and that the resulting share overhang could limit any near-term rebound in Amplifon’s share price.
GN confirmed it does not consider itself a long-term investor. The two parties said discussions on the sale ran for approximately six months, with GN citing payment certainty and what it viewed as a potentially easier regulatory pathway compared with a sale to a hearing-aid manufacturer.
Management projected run-rate net EBITDA synergies of €60 million to €80 million by the end of 2029, estimating that about 85% of those synergies would come from volume insourcing.
Barclays calculated that pro-forma net debt to EBITDA would be around 3 times at closing. The bank noted that this leverage could move closer to 4 times if the equity issuance were reduced to roughly 50% of the €0.75 billion cap.
Jefferies provided an earnings trajectory assessment that showed the transaction as roughly 2% dilutive to earnings per share in 2027 before becoming about 4% accretive in 2028.
Both banks also flagged potential competitive and wallet-share implications for other industry players, identifying Sonova and Demant as companies that could be negatively affected. Those two groups previously made up about 20% and 15% of Amplifon’s wallet respectively.
Market reaction to the deal was also visible in GN Store Nord’s stock, which rose 21.2% on March 16 on volume about 10.7 times its 60-day average.
Amplifon’s controlling shareholder, Ampliter, which holds 42.01% of share capital and 68.36% of voting rights, confirmed its support for the transaction and indicated it will participate in the equity raise.
Operational takeaways
- Amplifon shifts from a pure retail-only model toward an integrated owner of a manufacturing-related business, a strategic pivot characterized by higher leverage and potential near-term shareholder dilution.
- Management expects material synergies by 2029, driven predominately by insourcing volume, which will be critical to converting the transaction into cash-flow benefits over the medium term.
- Financing choices and equity issuance levels will influence pro-forma leverage and could determine whether the company remains closer to 3 times net debt to EBITDA or moves toward 4 times, with attendant implications for credit and capital allocation.